Leafy Tunnel
VC Fund
London, United Kingdom
Leafy Tunnel is an early-stage venture capital firm investing in alternative medicine to address mental health and pain disorders.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Leafy Tunnel invests in
Stages Leafy Tunnel invests in
Countries Leafy Tunnel invests in
Round sizes
Round size
- Seed
- $2M–$3.5M
Investment Focus
Industry
- Health Care 4 (100%)
- Medical 2 (50%)
- Life Science 2 (50%)
- Biotechnology 2 (50%)
- Cannabis 1 (25%)
Stage
- Seed 2 (50%)
- Series A 1 (25%)
- Series B 1 (25%)
Country
- United States 2 (50%)
- United Kingdom 2 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ceretype Neuromedicine
|
Ceretype Neuromedicine is an AI-based fMRI brain biomarker technology to improve drug discovery and patient care. Based in Cambridge Massachusetts, Ceretype is founded on seminal scientific discoveries made in the laboratory of Emily Stern, David Silbersweig, and Hong Pan at Brigham and Women’s Hospital/Harvard Medical School (BWH/HMS). | $2M / Seed / Jan 04, 2023 | |
Lyphe group
|
Lyphe group is a medical cannabis ecosystem providing patient care, medical treatments, and direct-2-patient digital services. | $6.3M / Series A / May 23, 2022 | |
Maya Health
|
Maya Health's mission is to improve psychedelic practitioners with the technology and data they need to scale safely and effectively, serve more people, and advance psychedelic healthcare. The company was founded in 2019 by David Champion and Akoni Anthony and is based in Denver, Colorado. | $3.5M / Seed / Dec 17, 2021 | |
Beckley Psytech
|
Beckley Psytech operates as a psychedelic medicine company. The company is involved in exploring the therapeutic potential of psychedelic substances, such as psilocybin and other compounds, for mental health treatment. The company envisions the integration of clinically validated psychedelic medicines into contemporary medical practices to assistindividuals coping with depression and other significantly debilitating neuropsychiatric conditions characterized by a substantial unmet need. | $80.4M / Series B / Aug 15, 2021 |
Co-Investors
One Mind Accelerator
2 deals together
Adage Capital Management
1 deal together
Ambria Capital
1 deal together
Bicycle Day Ventures
1 deal together
Delphi VC
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Leafy Tunnel invest in?
Leafy Tunnel invests primarily in Health Care, Medical and Life Science startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Leafy Tunnel's check size?
Leafy Tunnel typically joins rounds of $2M–$3.5M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Leafy Tunnel participates in.
When did Leafy Tunnel last invest?
The most recent investment recorded for Leafy Tunnel closed in Jan 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
